Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Barry I Eisenstein

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Expert Opinion on Drug Discovery|March 15, 2013
Use of daptomycin for treatment of Staphylococcus aureus infectionsBarry I Eisenstein
Expert Opinion on Investigational Drugs|August 28, 2004
Lipopeptides, focusing on daptomycin, for the treatment of Gram-positive infectionsBarry I Eisenstein
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 12, 2005
The clinical relevance and correct designation of isolates nonsusceptible to daptomycinJeff Alder, Barry I Eisenstein
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 14, 2010
Daptomycin: from the mountain to the clinic, with essential help from Francis Tally, MDBarry I Eisenstein, Frederick B Oleson, Richard H Baltz
Annals of the New York Academy of Sciences|May 7, 2014
The evolution of the regulatory framework for antibacterial agentsJohn H Rex, Mark Goldberger, Barry I Eisenstein, et al.
Expert Opinion on Investigational Drugs|January 31, 2003
Development potential of rifalazilDavid M Rothstein, Arthur D Hartman, Michael H Cynamon, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 23, 2010
Decreasing the probability of creatine phosphokinase elevations: clinical considerations for daptomycin dosing in obese patientsBrian J Donovan, John F Mohr, Andrew G Knapp, et al.
The Journal of Antimicrobial Chemotherapy|June 8, 2018
Towards a global definition of responsible antibiotic use: results of an international multidisciplinary consensus procedureAnnelie A Monnier, Barry I Eisenstein, Marlies E Hulscher, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 1, 2004
The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infectionsRobert D Arbeit, Dennis Maki, Francis P Tally, et al.
The Journal of Antimicrobial Chemotherapy|September 11, 2008
Daptomycin versus vancomycin plus gentamicin for treatment of bacteraemia and endocarditis due to Staphylococcus aureus: subset analysis of patients infected with methicillin-resistant isolatesSusan J Rehm, Helen Boucher, Donald Levine, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Expert Opinion on Drug Discovery|March 15, 2013
Use of daptomycin for treatment of Staphylococcus aureus infectionsBarry I Eisenstein
Expert Opinion on Investigational Drugs|August 28, 2004
Lipopeptides, focusing on daptomycin, for the treatment of Gram-positive infectionsBarry I Eisenstein
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 12, 2005
The clinical relevance and correct designation of isolates nonsusceptible to daptomycinJeff Alder, Barry I Eisenstein
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 14, 2010
Daptomycin: from the mountain to the clinic, with essential help from Francis Tally, MDBarry I Eisenstein, Frederick B Oleson, Richard H Baltz
Annals of the New York Academy of Sciences|May 7, 2014
The evolution of the regulatory framework for antibacterial agentsJohn H Rex, Mark Goldberger, Barry I Eisenstein, et al.
Expert Opinion on Investigational Drugs|January 31, 2003
Development potential of rifalazilDavid M Rothstein, Arthur D Hartman, Michael H Cynamon, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 23, 2010
Decreasing the probability of creatine phosphokinase elevations: clinical considerations for daptomycin dosing in obese patientsBrian J Donovan, John F Mohr, Andrew G Knapp, et al.
The Journal of Antimicrobial Chemotherapy|June 8, 2018
Towards a global definition of responsible antibiotic use: results of an international multidisciplinary consensus procedureAnnelie A Monnier, Barry I Eisenstein, Marlies E Hulscher, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 1, 2004
The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infectionsRobert D Arbeit, Dennis Maki, Francis P Tally, et al.
The Journal of Antimicrobial Chemotherapy|September 11, 2008
Daptomycin versus vancomycin plus gentamicin for treatment of bacteraemia and endocarditis due to Staphylococcus aureus: subset analysis of patients infected with methicillin-resistant isolatesSusan J Rehm, Helen Boucher, Donald Levine, et al.
Pageof 2